BeOne Medicines (ONC) Non-Current Debt (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Non-Current Debt data on file, last reported at $842.9 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 426.31% year-over-year to $842.9 million in Q1 2026; TTM through Mar 2026 was $842.9 million, a 426.31% increase from a year earlier, with the FY2025 full-year figure at $961.9 million, up 477.78% from the prior year.
• Non-Current Debt for Q1 2026 stood at $842.9 million, down from $961.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for ONC reached as high as $961.9 million in Q4 2025 and fell as low as $139.6 million in Q3 2025.
• Historically, Non-Current Debt has averaged $271.0 million across 5 years, with a median of $199.0 million in 2024.
• On a YoY basis, Non-Current Debt climbed as much as 477.78% in 2025 and fell as far as 25.57% in 2025.
• Year by year, Non-Current Debt stood at $209.1 million in 2022, then declined by 5.51% to $197.6 million in 2023, then dropped by 15.75% to $166.5 million in 2024, then surged by 477.78% to $961.9 million in 2025, then slipped by 12.37% to $842.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $842.9 million in Q1 2026, $961.9 million in Q4 2025, and $139.6 million in Q3 2025.